CASI Pharmaceuticals, Inc. (NasdaqCM:CASI) acquired ANDA portfolio of Sandoz Inc. for $18 million on January 26, 2018. CASI will pay Beijing Zhi He Kang Dao Biotechnology Co. Ltd, a closing fee equal to 3.5% of the purchase price for services in connection with the identification of the opportunity, performing China due diligence and market research. CASI Pharmaceuticals, Inc. (NasdaqCM:CASI) completed the acquisition of ANDA portfolio of Sandoz Inc. on January 26, 2018.